DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 25 mcg recall — FDA D-0123-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
Monthly breakdown
2024 recalls by month
Select a month to review the recall records reported during that period.
December 2024325 records · 4 categoriesNovember 2024355 records · 4 categoriesOctober 2024409 records · 4 categoriesSeptember 2024547 records · 4 categoriesAugust 2024327 records · 4 categoriesJuly 2024318 records · 4 categoriesJune 2024286 records · 4 categoriesMay 2024422 records · 4 categoriesApril 2024323 records · 4 categoriesMarch 2024332 records · 4 categoriesFebruary 2024425 records · 4 categoriesJanuary 2024298 records · 4 categories
2024 recalls — page 5
Records are ordered by the best available source date.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 75 mcg recall — FDA D-0125-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Timolol Maleate Ophthalmic Solution USP, 0.25%, Sterile, 15mL bottles recall — FDA D-0114-2025
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Class IIFDA: OngoingFDC Limited
DrugDec 18, 2024
Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials recall — FDA D-0116-2025
cGMP Deviations: Temperature excursion
Class IIFDA: TerminatedMckesson Medical-Surgical Inc. Corporate Office
DrugDec 18, 2024
Biocompatibles UK Varithena recall — FDA D-0113-2025
Defective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10 mL Luer Solo…
Class IIIFDA: TerminatedBiocompatibles UK, Ltd.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 88 mcg recall — FDA D-0126-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 137 mcg recall — FDA D-0119-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 175 mcg recall — FDA D-0121-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 112 mcg recall — FDA D-0128-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton recall — FDA D-0134-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 200 mcg recall — FDA D-0122-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 125 mcg recall — FDA D-0118-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
SEVERE COLD AND FLU PLUS CONGESTION Kirkland Severe Cold & Flu Plus Congestion: Day - 112 recall — FDA D-0115-2025
CGMP Deviations: Released product should have been rejected.
Class IIFDA: TerminatedLNK International, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton recall — FDA D-0132-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton recall — FDA D-0135-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton recall — FDA D-0131-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 50 mcg recall — FDA D-0124-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton recall — FDA D-0136-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton recall — FDA D-0133-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 100 mcg recall — FDA D-0127-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 150 mcg recall — FDA D-0120-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
VehicleDec 17, 2024
Tesla pressure monitoring and regulating systems recall — NHTSA campaign 24V935000
Tesla, Inc. (Tesla) is recalling certain 2024 Cybertruck, 2017-2025 Model 3, and 2020-2025 Model Y vehicles. The tire pressure monitoring system (TPMS) warning light may not remain…
pressure monitoring and regulating systemsTesla, Inc.
Medical DeviceDec 11, 2024
MEDLINE convenience kits labeled as: 2) ABDOMINAL LAPAROSCOPY, REF CDS760057K recall — FDA Z-0630-2025
Medline is recalling medical convenience manufactured using certain lots of SafeAir Smoke Evacuation Pencil which were subsequently recalled by Stryker.
Class IIFDA: OngoingMEDLINE INDUSTRIES, LP - Northfield
Medical DeviceDec 11, 2024
Wilson-Cook Medical Cook Medical HEMO-7-EU Hemospray Endoscopic Hemostat, REF G24663, 2.8 recall — FDA Z-0582-2025
Specific lots of product have been manufactured with nonconforming raw materials resulting in the red activation knob cracking or breaking at the activation knob internal threading while…
Class IIFDA: OngoingWilson-Cook Medical Inc.
About the 2024 recall archive
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.